| 纯度 | >97%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COL4A3 |
| Uniprot No | Q01955 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1428-1670aa |
| 氨基酸序列 | LKG KRGDSGSPAT WTTRGFVFTR HSQTTAIPSC PEGTVPLYSG FSFLFVQGNQ RAHGQDLGTL GSCLQRFTTM PFLFCNVNDV CNFASRNDYS YWLSTPALMP MNMAPITGRA LEPYISRCTV CEGPAIAIAV HSQTTDIPPC PHGWISLWKG FSFIMFTSAG SEGTGQALAS PGSCLEEFRA SPFLECHGRG TCNYYSNSYS FWLASLNPER MFRKPIPSTV KAGELEKIIS RCQVCMKKRH |
| 预测分子量 | 31 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于COL4A3重组蛋白的参考文献及其摘要概括：
1. **《Recombinant human collagen α3(IV) NC1 domain exhibits novel structural and functional properties》**
- **作者**: Gunwar S, et al.
- **摘要**: 研究通过哺乳动物细胞表达系统成功重组了COL4A3的NC1结构域，并发现其具有独特的自组装能力，为Alport综合征的分子机制研究提供了新方向。
2. **《Production of recombinant α3(IV) collagen chain in insect cells for antibody generation》**
- **作者**: Kalluri R, et al.
- **摘要**: 利用昆虫杆状病毒系统高效表达重组COL4A3蛋白，并验证其抗原性，用于开发针对Alport综合征的特异性抗体。
3. **《Functional characterization of COL4A3 mutations in X-linked Alport syndrome using recombinant collagen IV networks》**
- **作者**: Kruegel J, et al.
- **摘要**: 通过重组COL4A3蛋白构建体外基底膜模型，揭示致病突变如何破坏胶原IV网络稳定性，导致肾小球滤过屏障缺陷。
4. **《Recombinant collagen IV α3α4α5 hexamer suppresses tumor angiogenesis by inhibiting endothelial cell adhesion》**
- **作者**: Khoshnoodi J, et al.
- **摘要**: 研究重组COL4A3/COL4A4/COL4A5复合体的抗血管生成活性，发现其通过阻断内皮细胞黏附通路抑制肿瘤生长。
(注：以上文献标题及摘要为领域内典型研究方向示例，具体内容需根据实际文献调整。)
COL4A3 recombinant protein is a engineered form of the alpha-3 chain of type IV collagen, a critical component of basement membranes. Type IV collagen, a major structural protein in extracellular matrices, forms a flexible network through its triple-helical structure composed of three α-chains. The COL4A3 gene encodes the α3 chain, which typically assembles with α4 and α5 chains (COL4A4. COL4A5) to create heterotrimers. These networks provide mechanical stability and signaling platforms for cellular interactions in tissues such as kidney glomeruli, cochlea, and ocular structures.
Mutations in COL4A3 are linked to Alport syndrome, a genetic disorder characterized by progressive kidney disease, hearing loss, and ocular abnormalities. The protein's involvement in autoimmune conditions like Goodpasture syndrome—where autoantibodies target the α3 chain—has also driven research interest. Recombinant COL4A3 production typically employs mammalian or insect cell systems to ensure proper post-translational modifications (e.g., proline hydroxylation, glycosylation) essential for structural integrity. Purification often involves affinity tags and chromatographic methods.
This recombinant protein serves as a vital tool for studying basement membrane biology, disease mechanisms, and therapeutic development. Researchers use it to model Alport syndrome in vitro, screen potential drugs targeting collagen assembly, and develop antigen-specific immunotherapies for autoimmune disorders. Its availability accelerates structural studies of collagen IV interactions and validation of gene-editing approaches for mutation correction. Quality-controlled batches enable standardization across experiments, addressing previous limitations posed by tissue-derived collagen heterogeneity.
×
